advertisement

Topcon

Grus FH 13

Showing records 1 to 13 | Display all abstracts from Grus FH

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Anders F
PLoS ONE 2017; 12: e0175451
72603 The potential impact of recent insights into proteomic changes associated with glaucoma
Funke S
Expert review of proteomics 2017; 14: 311-334
73522 Modulation of the immune system for the treatment of glaucoma
Bell K; Und Hohenstein-Blaul NVT
Current Neuropharmacology 2017; 0:
72603 The potential impact of recent insights into proteomic changes associated with glaucoma
Perumal N
Expert review of proteomics 2017; 14: 311-334
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Teister J; Liu A
PLoS ONE 2017; 12: e0175451
73522 Modulation of the immune system for the treatment of glaucoma
Teister J
Current Neuropharmacology 2017; 0:
72603 The potential impact of recent insights into proteomic changes associated with glaucoma
Bell K
Expert review of proteomics 2017; 14: 311-334
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Funke S
PLoS ONE 2017; 12: e0175451
73522 Modulation of the immune system for the treatment of glaucoma
Grus FH
Current Neuropharmacology 2017; 0:
72603 The potential impact of recent insights into proteomic changes associated with glaucoma
Pfeiffer N
Expert review of proteomics 2017; 14: 311-334
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Grus FH
PLoS ONE 2017; 12: e0175451
72603 The potential impact of recent insights into proteomic changes associated with glaucoma
Grus FH
Expert review of proteomics 2017; 14: 311-334
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Thanos S; von Pein HD; Pfeiffer N; Prokosch V
PLoS ONE 2017; 12: e0175451

Issue 18-4

Change Issue


advertisement

Oculus